Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
Prospective assessment of real-time homologous recombination repair via nuclear RAD51 levels shows promise but needs validation. Emerging biomarkers like ADP-ribosylation, HOXA9 promoter methylation, patient-derived organoids, KELIM, and SLFN11 offer potential but require large-scale validation.
Authors
- Marc Tischkowitz (ORCID: https://orcid.org/0000-0002-7880-0628)
- Ying-Wen Wang (ORCID: https://orcid.org/0000-0003-1997-5521)
- Isaac Allen (ORCID: https://orcid.org/0000-0003-4640-3617)
- Yvonne Walburga Joko-Fru (ORCID: https://orcid.org/0000-0001-6233-4936)
- Gabriel Funingana
Institutions
- Harvard University (US)
- University of Cambridge (GB)
- National Institute for Health and Care Research (GB)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1038/s44276-025-00122-9
- Citations
- 7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- NIHR Cambridge Biomedical Research Centre